newsfilter
← Latest News
PR Newswire·

Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody progr